Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma

Open access
Gandola, Lorenza, Massimino, Maura, Cefalo, Graziella, Solero, Carlo, Spreafico, Filippo, Pecori, Emilia, Riva, Daria, Collini, Paola, Pignoli, Emanuele, Giangaspero, Felice, Luksch, Roberto, Berretta, Serena, Poggi, Geraldina, Biassoni, Veronica, Ferrari, Andrea, Pollo, Bianca, Favre, Claudio, Sardi, Iacopo, Terenziani, Monica, Fossati-Bellani, Franca · 2009 · Journal of Clinical Oncology

Abstract

Purpose: With a view to improving the prognosis for patients with metastatic medulloblastoma, we tested the efficacy and toxicity of a hyperfractionated accelerated radiotherapy (HART) regimen delivered after intensive sequential chemotherapy. Patients and Methods: Between 1998 and 2007, 33 consecutive patients received postoperative methotrexate (8 g/m 2 ), etoposide (2.4 g/m 2 ), cyclophosphamide (4 g/m 2 ), and carboplatin (0.8 g/m 2 ) in a 2-month schedule, then HART with a maximal dose to the neuraxis of 39 Gy (1.3 Gy/fraction, 2 fractions/d) and a posterior fossa boost up to 60 Gy (1.5 Gy/fraction,2 fractions/d). Patients with persistent disseminated disease before HART were consolidated with two myeloablative courses and circulating progenitor cell rescue. Results: Patients were classified as having M1 (n = 9), M2 (n = 6), M3 (n = 17), and M4 (n = 1) disease. Seven patients younger than 10 years old who achieved complete response after chemotherapy received a lower dose to the neuraxis (31.2 Gy). Twenty-two of the 32 assessable patients responded to chemotherapy; disease was stable in five patients and progressed in five patients. One septic death occurred before radiotherapy. Eight patients experienced relapse after a median of 12 months. Fourteen of the 33 patients underwent consolidation therapy after HART. With a median 82-month survivor follow-up, the 5-year event-free, progression-free, and overall survival rates were 70%, 72%, and 73%, respectively. No severe clinical complications of HART have emerged so far. Conclusion: HART after intensive postoperative chemotherapy, followed by myeloablative chemotherapy in selected cases, proved feasible in children with metastatic medulloblastoma. The results of our treatment compare favorably with other series treated using conventional therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.18.4176

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 175

Metadata

Authors
Gandola, L., Massimino, M., Cefalo, G., Solero, C., Spreafico, F., Pecori, E., Riva, D., Collini, P., Pignoli, E., Giangaspero, F., Luksch, R., Berretta, S., Poggi, G., Biassoni, V., Ferrari, A., Pollo, B., Favre, C., Sardi, I., Terenziani, M., & Fossati-Bellani, F.
Venue
Journal of Clinical Oncology
Published
2009-02-01
Volume
27
Issue
4
Pages
566-571
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2161396647
Cited by
175
References
1
FWCI
1.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma. https://app.cochat.ai/papers/10.1200/jco.2008.18.4176
The paper
Gandola, L., Massimino, M., Cefalo, G., Solero, C., Spreafico, F., Pecori, E., Riva, D., Collini, P., Pignoli, E., Giangaspero, F., Luksch, R., Berretta, S., Poggi, G., Biassoni, V., Ferrari, A., Pollo, B., Favre, C., Sardi, I., Terenziani, M., & Fossati-Bellani, F. (2009). Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.18.4176

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.